TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24307502
Drug: Extended oral
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended oral antimicrobials for 8 days postoperatively (Group II)
Study: 22382787
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride capsule (20 mg, test)
Study: 22382787
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride tablet (20 mg, reference)
Study: 20560981
Drug: fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160 mg daily for 8 weeks
Study: 20560981
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment for 8 weeks (control)
Study: 17556347
Drug: Time‐to‐treatment delay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time‐to‐treatment delay
Study: 12407040
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg oral misoprostol twice daily (days 4-10)
Study: 12407040
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg vaginal misoprostol and placebo
Study: 7979285
Drug: Valaciclovir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 1,000 mg four times daily for 30 days
Study: 7979285
Drug: Valaciclovir 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 2,000 mg four times daily for 30 days
Study: 3377946
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine 3 mg
Study: 3377946
Drug: Buprenorphine 0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.18 mg
Study: 3377946
Drug: Buprenorphine 0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.09 mg
Study: 3377946
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (morphine 3 mg, buprenorphine 0.18 mg, buprenorphine 0.09 mg)
Study: 3377946
Drug: Morphine 3
Normalized name: apomorphine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 3 mg and buprenorphine 0.18 mg
Study: 24337919
Drug: Invasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive therapy (primary PCI)
Study: 17551699
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg chlorazepate dipotassium (CD) in the evening and 25 mg CD in the morning, placebo 30 min prior to anesthesia
Study: 17551699
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg midazolam on demand, placebo in the evening
Study: 11452128
Drug: Activation of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activation of mu-opioid receptor system
Study: 9452284
Drug: Artesunate suppositories
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate suppositories (15 mg/kg/day for three days)
Study: 9452284
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (6 mg/kg/day for three days)
Study: 7629484
Drug: Methimazole 60
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 60 mg day‐1 combined with thyroxine
Study: 7629484
Drug: Methimazole alone
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole alone (low-dose)
Study: 7629484
Drug: Intention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intention to treat analysis for high-dose group
Study: 7629484
Drug: Intention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intention to treat analysis for low-dose group
Study: 2774647
Drug: Suspension-type ointment
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney) / poliovirus vaccine inactivated, type 2 (MEF-1) / poliovirus vaccine inactivated, type 3 (Saukett) Injectable Suspension [Ipol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension-type ointment (0.0056% betamethasone-17-benzoate)
Study: 2774647
Drug: Solution-type ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-type ointment (0.0056% betamethasone-17-benzoate)
Study: 779588
Drug: Debrisoquine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debrisoquine (3 X 10 mg daily)
Study: 779588
Drug: Methyldopa (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (3 X 250 mg daily)
Study: 28838980
Drug: Fevipiprant 150
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant 150 mg q.d
Study: 28838980
Drug: Fevipiprant 75
Normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant 75 mg b.i.d
Study: 28838980
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg q.d
Study: 21426664
Drug: Weekly usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly usage of paclitaxel (45 mg/m², 1 time/week, total 270 mg/m² in 6 weeks)
Study: 21426664
Drug: Triple weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple weekly usage of paclitaxel (15 mg/m², 3 times/week, total 270 mg/m² in 6 weeks)
Study: 17876174
Drug: Enhanced decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced decision aid (previous digital rectal examination)
Study: 17876174
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care decision aid (previous digital rectal examination)
Study: 11208880
Drug: Surgery, tamoxifen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, tamoxifen, and chemotherapy
Study: 1515565
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg per os
Study: 6540930
Drug: Conventional palliative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional palliative regimen without corticoid therapy
Study: 19597011
Drug: Maternal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal and infant antiretroviral therapy, elective cesarean section, avoidance of breast-feeding
Study: 19597011
Drug: Unmet need
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unmet need for antiretroviral therapy
Study: 11172505
Drug: Triple-injection method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-injection method (group III) - ulnar nerve not located
Study: 11172505
Drug: Four-injection method
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-injection method (group IV) - all nerves located
Study: 28089080
Drug: Salba‐chia (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salba‐chia (30 g/1000 kcal/day)
Study: 28089080
Drug: Oat bran-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran-based control (36 g/1000 kcal/day)
Study: 21269346
Drug: Weekly Unna
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Unna boot therapy
Study: 10705939
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of symptoms, type of gamma‐camera or radiopharmaceutical agent used.
Study: 9493655
Drug: Zileuton (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton (400 mg)
Study: 19882857
Drug: Standard complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard complex therapy without UVABI
Study: 14510038
Drug: Limited case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited case management services from primary drug counselors
Study: 14510038
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug use
Study: 9339804
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 microg/ml), 5 drops three times a day for 10 days
Study: 9339804
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate (5 mg/ml), 5 drops three times a day for 10 days
Study: 2412037
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg, b.i.d. for 2 weeks, then doubled)
Study: 2412037
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg, b.i.d. for 2 weeks, then doubled)
Study: 30160787
Drug: 2% tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% tofacitinib ointment applied twice daily
Study: 30160787
Drug: 1% ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ruxolitinib ointment
Study: 30160787
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol dipropionate 0.005% ointment
Study: 23900641
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of L‐3,4‐dihydroxyphenylalanine (L‐DOPA)
Study: 16860613
Drug: AGA II
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGA II compared to antitissue transglutaminase antibodies
Study: 10870980
Drug: SK and
Normalized name: Ispaghula husk and mebeverine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK and F 107647 (1, 10, 100, 500, and 1000 μg/kg as single 15-minute iv infusion)
Study: 10870980
Drug: SK and
Normalized name: Ispaghula husk and mebeverine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK and F 107647 (0.001, 0.01, 0.1 and 1 μg/kg as 2-hour iv infusions once daily for 10 days)
Study: 1900978
Drug: Flecainide 150
Normalized name: flecainide 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 150 mg twice per day for 3 months
Study: 25450717
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 8 mg
Study: 28369415
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 25 mg
Study: 25450717
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 40 mg
Study: 25450717
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 120 mg
Study: 28404092
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate 300 mg
Study: 9208343
Drug: Maalox 70
Normalized name: Maalox
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox 70 suspension (10 ml) with cerivastatin (200 micrograms)
Study: 9208343
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg b.i.d. for 4 days) with cerivastatin (200 micrograms)
Study: 7708405
Drug: Nasal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal capsaicin treatment on the ipsilateral side
Study: 7708405
Drug: Nasal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal capsaicin treatment on the contralateral side
Study: 7708405
Drug: Nasal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal capsaicin treatment for chronic patients (ipsilateral and contralateral alternately)
Study: 7708405
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of ipsilateral vs contralateral treatment
Study: 3616278
Drug: Single-dose trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose trimethoprim 400 mg once
Study: 3616278
Drug: Multi-dose trimethoprim
Normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose trimethoprim 200 mg twice daily for five days
Study: 26892939
Drug: High-dose unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose unilateral ECT
Study: 20299496
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy including lopinavir/ritonavir
Study: 12517650
Drug: Intraabdominal irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraabdominal irrigation with normal saline (500-1000 mL)
Study: 10769584
Drug: Ramipril at
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril at a dose of 10 mg/day
Study: 10769584
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplements at a dose of 400 UI/day
Study: 8804873
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (colloidal bismuth subcitrate 480 mg/day plus metronidazole 750 mg/day and tetracycline 1000 mg/day for 4 weeks)
Study: 12360598
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day for 8 weeks
Study: 6496919
Drug: Heparin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin + 1000 units of purified human antithrombin III (AT III) concentrate
Study: 1497392
Drug: Heparin only
Normalized name: Heparin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin only
Study: 28527204
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose LEV (2.5 mg/kg)
Study: 28527204
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose LEV (7.5 mg/kg)
Study: 26097215
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg every 4 weeks)
Study: 24199969
Drug: Qigong training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qigong training (twice a week for 10 weeks)
Study: 21891890
Drug: HA+200 μg
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HA+200 μg drug solution of ALN
Study: 19696601
Drug: Individualized Acu/Moxa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized Acu/Moxa treatment
Study: 12943880
Drug: Jo heparin‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jo heparin‐coated stent deployment
Study: 1632658
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day by mouth
Study: 6489428
Drug: Acetaminophen 12‐14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 12‐14 mg/kg
Study: 6489428
Drug: Acetaminophen 22‐27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 22‐27 mg/kg
Study: 6489428
Drug: Acetaminophen repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen repeated doses every 4 or 8 h for 1 to 3 days
Study: 6489428
Drug: Acetaminophen repeated
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen repeated doses
Study: 29020483
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), applied three times weekly.
Study: 20713433
Drug: Broccoli intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli intake (250 g/day)
Study: 17553051
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amorolfine hydrochloride 5% nail lacquer once weekly for 12 months plus terbinafine 250 mg once daily for 3 months (AT group)
Study: 17553051
Drug: Terbinafine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine alone once daily for 3 months (T group)
Study: 12117037
Drug: Airmax inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airmax inhaler at fast flow rate (60 l min(‐1))
Study: 12117037
Drug: Turbuhaler at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler at fast flow rate (60 l min(‐1))
Study: 12117037
Drug: Airmax inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airmax inhaler at slow flow rate (30 l min(‐1))
Study: 12117037
Drug: Turbuhaler at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler at slow flow rate (30 l min(‐1))
Study: 12117037
Drug: pMDI at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI at slow flow rate (30 l min(‐1))
Study: 7487784
Drug: Psychiatric case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric case management using an assertive community treatment model involving general practitioners
Study: 2151518
Drug: Domperidone (DMP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DMP; 20 mg orally)
Study: 7422533
Drug: Oral pentaerythritol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentaerythritol tetranitrate
Study: 7422533
Drug: Oral pentaerythritol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentaerythritol tetranitrate (high dosage)
Study: 21297567
Drug: BCAA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA (300 mg . kg . day ‐1)
Study: 10406241
Drug: ASA/PC (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA/PC (Aspirin associated with phosphatidylcholine)
Study: 10406241
Drug: ASA (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (Aspirin alone)
Study: 26022813
Drug: Dalcetrapib (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (a cholesteryl ester transfer protein inhibitor)
Study: 10430816
Drug: Oral antihyperglycemic
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihyperglycemic agents
Study: 7558380
Drug: Testosterone enanthate,
Normalized name: Testosterone Enanthate, enanthate 200 mg/mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate, 200 mg IM, weekly injections during the suppression (6‐month) and efficacy (12‐month) phases.
Study: 496621
Drug: 1000‐IU vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000‐IU vitamin E capsules (alpha‐tocopherol) administered daily for 28 days
Study: 496621
Drug: 1000‐IU vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000‐IU vitamin E capsules (alpha‐tocopherol)
Study: 30650245
Drug: Group-based mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based mindfulness-based cognitive therapy (MBCT)
Study: 28574379
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for DFS
Study: 28574379
Drug: Cytoflavin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin 10 ml 0.9% NaCl 200 ml for 10 days, followed by 2 tablets 2 times per day orally for one month
Study: 25029675
Drug: Multi-ingredient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient supplement enriched with l-glutamine and l-carnitine-l-tartrate
Study: 25029675
Drug: Carbohydrate supplement
Normalized name: carbohydrate supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplement
Study: 25029675
Drug: Multi-ingredient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient supplement
Study: 19056578
Drug: Glutamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (30 g)
Study: 17242107
Drug: Conventional catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheter (CC group)
Study: 12475466
Drug: Carvedilol (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (0.01 mg/kg/day titrated up to 0.2 mg/kg/day)
Study: 9535429
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin daily
Study: 9535429
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg daily
Study: 7608438
Drug: L-carnitine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (9 g/day intravenously for the first 5 days, then 6 g/day orally for 12 months)
Study: 23958241
Drug: Pioglitazone, 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone, 45 mg/d for 6 months
Study: 23958241
Drug: Metformin, 2
Normalized name: Glipizide-Metformin, 2.5 mg-250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 2 g/day added after pioglitazone
Study: 15236870
Drug: Chemoradiation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation to a total dose of 50.4Gy (1.8Gy per fraction) with two courses of bolus 5-fluorouracil and leucovorin
Study: 11736860
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg diazepam i.n.
Study: 11736860
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg diazepam i.n.
Study: 11736860
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous diazepam
Study: 8214649
Drug: Propofol 1-2
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1-2 mg/kg for induction and sufentanil 0.03 micrograms.kg-1.min-1 plus propofol 50-200 micrograms.kg-1.min-1 for maintenance (Group A)
Study: 22661750
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6 ml kg(‐1) predicted body weight)
Study: 22661750
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume ventilation (12 ml kg(‐1) predicted body weight)
Study: 20200338
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ibudilast
Study: 20200338
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ibudilast
Study: 20200338
Drug: Ibudilast (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (both doses)
Study: 12919884
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) at 0.12 mJ/mm(2)
Study: 10329871
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered misoprostol (50 micrograms every 4 hours)
Study: 10329871
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered misoprostol (25 micrograms every 4 hours)